Access to Justice

PLIVA, Inc. v. Mensing

At issue in PLIVA, Inc. v. Mensing was whether state law claims against generic drug manufacturers for failing to properly warn consumers about dangerous risks associated with their products should be displaced by federal law.

Case Summary

On March 2, 2011, CAC filed an amicus curiae brief in the Supreme Court in PLIVA, Inc. v. Mensing. At issue in this case was whether state law claims against generic drug manufacturers for failing to properly warn consumers about dangerous risks associated with their products should be displaced by federal law. The PLIVA case was virtually identical to 2009’s Wyeth v. Levine, in which the Court held that state failure-to-warn claims against brand-name prescription drug manufacturers are not preempted by the Federal Food, Drug and Cosmetic Act (FDCA).

Gladys Mensing and Julie Demahy sued the generic manufacturers of the drug metoclopromide, which caused them to have serious adverse effects, alleging that they were injured because the drug manufacturers failed to adequately warn that long-term use of their generic drug could cause severe, harmful side effects. The generic drug manufacturers countered that, because federal law requires them to use the same label as the relevant brand-name drug, they cannot be held liable for the contents of the label. However, the U.S. Court of Appeals for the Eighth Circuit held that federal law provides for several mechanisms by which generic drug manufacturers can seek to change the label or otherwise warn consumers and physicians about risks, and therefore that state law liability can coexist with federal generic drug regulations.

CAC’s brief in PLIVA, like our brief in Wyeth, argued that state common law claims should be allowed to work in conjunction with FDA oversight, as neither the Constitution nor the principles behind it support displacing the States’ traditional role in protecting consumer safety and health in the absence of a direct conflict between state and federal law. In this case, there is nothing in the statutory text of the Hatch-Waxman Amendments to the FDCA, which encouraged the development of low-cost generic drugs, to suggest that the Amendments were intended to override the FDCA’s general preservation of state tort remedies as a complementary form of consumer protection.

The Court heard oral argument in PLIVA on March 30, 2011. CAC’s wrap-up of the oral argument is here.

On June 23, 2011, in an ideologically divided ruling, the Supreme Court held, 5-4, that generic drug manufacturers may not be sued under state failure-to-warn laws because it would be “impossible” for the generic drug manufacturers to comply with both state law and federal law. Read our statement decrying the ruling here. For an in-depth analysis of this decision, visit our blog Text & History.

Case Timeline

More from Access to Justice

Access to Justice
May 9, 2024

RELEASE: In overbroad ruling, conservative majority restricts the rights of innocent car owners whose vehicles are seized by the government

WASHINGTON, DC – Following today’s decision at the Supreme Court in Culley v. Marshall, a...
By: Brian R. Frazelle
Access to Justice
U.S. Supreme Court

Williams v. Washington

In Williams v. Washington, the Supreme Court is considering whether states may force civil rights litigants who bring claims against state officials in state court under Section 1983 to first exhaust their administrative remedies.
Access to Justice
April 12, 2024

RELEASE: Court Unanimously Rejects Atextual “Transportation Industry” Requirement for FAA Exemption, Allowing Truck Drivers Their Day in Court

WASHINGTON, DC – Following today’s decision at the Supreme Court in Bissonnette v. LePage Bakeries...
By: Miriam Becker-Cohen
Access to Justice
March 20, 2024

RELEASE: Justices Weigh Immunity for Government Officials Who Target Political Adversaries with Arrest

WASHINGTON, DC – Following oral argument at the Supreme Court this morning in Gonzalez v....
By: Brian R. Frazelle
Access to Justice
February 20, 2024

RELEASE: Court Grapples Once Again with Federal Arbitration Act’s Exemption for Transportation Workers

WASHINGTON, DC – Following oral argument at the Supreme Court this morning in Bissonnette v....
By: Miriam Becker-Cohen
Access to Justice
February 19, 2024

Bakery Drivers Head to High Court Searching for Arbitration Exit

Bloomberg Law
Industry test would add fights on transportation firm meaning With circuits split, high court to...
By: Miriam Becker-Cohen, Jennifer Bennett